Warmer summers and other factors have experts predicting the polar bear may not be able to deal with a warming climate.» Read More
The effects of climate change could reduce the world's largest collection of coral reef, an area about the size of Japan, to a sliver of itself.
The ability to unfold a protein and return it to its original state could save money in everything from cancer research to food production.
A team of researchers in Scotland found that changing the shape of light can slow it down, meaning the speed of light is not as constant as thought.
An association of top scientists has moved the hand of the symbolic Doomsday Clock, over the threats of nuclear weapons and warming climates.
The chief of California's state-run earthquake insurance agency says residents there have no financial protection if a big quake hits.
Scientists lost contact with the Beagle 2 before it was supposed to land on Mars on Christmas Day 2003. NASA images have just shown it.
Bill Nye, "The Science Guy" weighs in on how to fix the US's problem of not being able to fill millions of STEM jobs.
Scientists coated fabric with a nearly invisible substance that can supercharge winter clothing and cut down on household heating.
Anne Wojcicki, co-founder and CEO of genetic-testing startup 23andMe, discusses the new deals with Pfizer and Genentech.
CNBC's Meg Tirrell speaks to Robert Hugin, Celgene chairman & CEO, about the company's ambitious long-term guidance and broad-based drug pipeline.
Superbugs are one of the biggest public health crises facing the world right now. CNBC's Meg Tirrell reports nature is sparking hope for scientists.
CNBC's Meg Tirrell reports an FDA advisory panel unanimously recommended approval of what would be the first generic biologic drug in the U.S.
Shares of Alkermes are up nicely after positive data from its schizophrenia drug trial. Richard Pops, Alkermes CEO, provides insight to the enormous market for schizophrenia and depression.
Discussing the outlook on the pharmaceutical sector, including leaders like Gilead and Celgene, with Michael Yee, RBC Capital Markets biotech analyst.
NBC's Harry Smith discusses just who is making the most money in the pot industry, and Starbuds owner Brian Ruden, discusses the cash issue with banks. CNBC's special "Marijuana Country: The Cannabis Boom" airs Monday night at 9PM eastern time.
NBC's Harry Smith looks at the thriving marijuana black market in Colorado even after legalization there. The special airs Monday night at 9PM eastern time.
NBC's Harry Smith provides a preview of CNBC's documentary on the benefits and pitfalls from medicinal marijuana. The special airs Monday night at 9PM eastern time.
A lab technician at the CDC has been placed under observation for possible exposure to the Ebola virus due to an apparent mix-up in lab specimens.
The battle to limit the sky-high cost of treating hepatitis C is heating up after Express Scripts announced it will put its weight behind a drug made by AbbVie and it will no longer cover Gilead's Sovaldi.
Insight to a potential $100 trillion problem by 2050, with Jim O'Neill, Fmr. Goldman Sachs Asset Management Chairman.